 |
| August
6, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
CEO WEEKLY Q&A:
Todd Dickinson, President & CEO,
Stellaromics |
| In
this Q&A, Dickinson explains why
conventional spatial platforms lose
critical biological information by cutting
tissue too thin, how its Pyxa® platform
preserves native tissue architecture in
sections up to 100 microns thick, and what
that means for drug discovery, tumor
biology, and patient care. More
|
|
|
- Broad Institute: Cancer Dependency Map Now
Includes Next-Generation 3D Cancer Models More
- Dana-Farber Cancer Institute: Collaborative
Team Doubles Number of In Vitro
Patient-Derived Cancer Models Available for
Research More
- Dana-Farber Cancer Institute: Investigators
Develop Protein Degrader Discovery Platform
and Find First-in-Kind Metabolically Activated
Molecular Glue Degrader
More
- Galibra Neuroscience: Receives FDA Orphan
Drug and Rare Pediatric Disease Designations
for SSADH Deficiency Gene Therapy More
- Insilico Medicines: AI-empowered
Pipeline-in-a-drug Option - Nominates ISM9077,
Potential First-in-class Target Y Inhibitor,
as Preclinical Candidate (PCC) for Ocular
Diseases, Inflammatory Disorders and Aging More
- Moderna: Receives U.S. FDA Approval for
Influenza Vaccine mFLUSIVA More
More
More
More*
More*
- Obsidian Therapeutics: First Patient
Enrolled in the Registration-enabling Cohort
of Phase 1/2 Agni-01 Study Evaluating
Amsoki-cel (OBX-115) in Advanced Melanoma More
- PepGen: Will Advance PGN-EDODM1 Into Highest
Dose Cohort in Phase 2 FREEDOM2-DM1 Study
Following DSMB Review More
- Takeda: U.S. FDA Approves ORZEYFUL
(oveporexton), the First and Only Medicine
to Treat the Underlying Cause of Narcolepsy
Type 1 More
More* More*
More*
|
|
 |
CRCFO
Advisory
Reassessing your business plan?
We provide financial leadership.
Smart. Nimble. Flexible. |
|
Learn More
→ |
|
|
- Agenus: Second Quarter 2026 Results and
Advances Phase 3 ROBBIN Trial of BOT+BAL in
Neoadjuvant MSS Colon Cancer More
- Akebia Therapeutics: Second Quarter 2026
Financial Results and Business Highlights More
- Amylyx Pharmaceuticals: Second Quarter 2026
Financial Results More
- BioPharmCatalyst Weekly Watchlist: Phase 3
Catalysts Remaining for the Quarter
More
- Black Diamond Therapeutics: Second Quarter
2026 Financial Results and Corporate Update More
- Collegium: Second Quarter 2026 Financial
Results and Highlights Recent Company Progress
More
- Corbus Pharmaceuticals: Q2 2026 Financial
Results and Provides a Corporate Update More
- Cullinan Therapeutics: Corporate Update and
Reports Second Quarter 2026 Financial Results
More
- Editas Medicine: Second Quarter 2026 Results
and Business Updates More
- Foghorn Therapeutics: Second Quarter 2026
Financial and Corporate Update More
- Generate Biomedicines: Second Quarter 2026
Financial Results and Provides Business Update
More
- Intellia Therapeutics: Second Quarter 2026
Financial Results and Business Updates More
- Ironwood Pharmaceuticals: Raises 2026
Full-Year Financial Guidance Building on
Strong Second Quarter Results More
- Korro: Second Quarter 2026 Financial Results
and Provides Corporate Update More
- LifeMine: Raises $263 Million to
Accelerate the Clinical Development of
LIFE-001, a Structurally and Mechanistically
Novel Calcineurin Activation Inhibitor
Designed to Transform Organ Transplantation
More
More
More*
More*
- Monte Rosa Therapeutics: Second Quarter 2026
Financial Results and Business Updates More
- More on Seres Therapeutics Exiting More
Cambridge Real Estate Early More*
- Myomo: Second Quarter 2026 Financial and
Operating Results More
- Ono Pharma: Enters Into a Drug Discovery
Partnership With Mediar Therapeutics to Create
Novel Antibody Therapeutics for
Fibro-inflammatory Diseases More
- PepGen: Second Quarter 2026 Financial
Results and Recent Corporate Highlights More
- Praxis Precision Medicines: Corporate Update
and Reports Second Quarter 2026 Financial
Results More
- Sarepta Therapeutics: Second Quarter 2026
Financial Results and Recent Corporate
Developments More
- Scholar Rock: Second Quarter 2026 Financial
Results and Recent Business Highlights More
- Seres Therapeutics Exits More Cambridge Real
Estate Early More*
- SMID Cap Earnings in Brief: BioNTech,
Moderna, Vertex, TG Therapeutics, Rhythm &
Travere More*
- Spero Therapeutics: Inducement Grant Under
Nasdaq Listing Rule 5635(c)(4) More
- Sionna Therapeutics: Second Quarter 2026
Financial Results More
- Standard BioTools: Second Quarter 2026
Financial Results More
- Vedanta Biosciences: Secures $60 Million
in Funding and Strengthens Leadership Team
Ahead of Pivotal Phase 3 Data More
More*
- Viridian Therapeutics: Highlights Recent
Business Progress and Reports Second Quarter
2026 Financial Results More
- Wave Life Sciences: Expected Completion Date
for Redomiciliation to Delaware More
- Zai Lab: Second Quarter 2026 Financial
Results and Recent Corporate Updates More
- Zevra: Second Quarter 2026 Financial Results
and Corporate Update More
|
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- Big4Bio CEO Weekly Q&A: Todd
Dickinson, President & CEO, Stellaromics
More
- COVID-19 Reactivates Dormant Viruses,
Offering New Clues to Long COVID More
More*
- Fecal Microbiome Transplant in Food Allergy
in Humans and Mice Identifies a Role for Bile
Acid Metabolites in Oral Tolerance More*
More*
More
- More on Enveric Biosciences Saying New
Preclinical Data Confirms Non-Hallucinogenic
Profile for Lead Psychiatric Candidate
More
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
 |
- Harbour BioMed: Appoints Dr. Bob Zhang as
President of Metabolic Disease Franchise to
Accelerate Global Development of Innovative
Therapies More
- ICYMI: Editas Medicine Strengthens Board of
Directors With Appointment of Patrick T.
Ellinor, M.D., Ph.D. More
- ICYMI: 5 NextGen Winners Who Went Public
This Year (and Which Ones Are Hiring) More
- ICYMI: Onshoring Is Here. The Hiring Wave Is
Still a Decade Out More
- OPPORTUNITY: Chief Scientific Officer,
Manassas, VA
More
- OPPORTUNITY: President, PA More
- OPPORTUNITY: Vice President, Global BD,
Remote More
- Over 1/3 Stay in Biopharma Jobs for Health
Insurance, Poll Finds
More
- Slone Partners: Places Amer Mirza, PhD, as
Chief Scientific Officer at Prolynx More
- Slone Partners: Places
Farhad Ghavami as Chief Executive Officer at
SeqCenter
More
- Slone Partners: The Convergence of
MedTech and Digital Health - How New Hybrid
Devices Are Reshaping Care Delivery and
Leadership Profiles More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
